MX2023011733A - Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin. - Google Patents

Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin.

Info

Publication number
MX2023011733A
MX2023011733A MX2023011733A MX2023011733A MX2023011733A MX 2023011733 A MX2023011733 A MX 2023011733A MX 2023011733 A MX2023011733 A MX 2023011733A MX 2023011733 A MX2023011733 A MX 2023011733A MX 2023011733 A MX2023011733 A MX 2023011733A
Authority
MX
Mexico
Prior art keywords
treatment
methods
small
cell lung
lung carcinoma
Prior art date
Application number
MX2023011733A
Other languages
English (en)
Inventor
Anita Reddy
Janet Yikai Jin
Phillip B Komarnitsky
Miirella Lazarov
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of MX2023011733A publication Critical patent/MX2023011733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona métodos mejorados para el tratamiento de cánceres de NSCLC usando telisotuzumab vedotin..
MX2023011733A 2021-04-06 2022-04-06 Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin. MX2023011733A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171571P 2021-04-06 2021-04-06
US202163171536P 2021-04-06 2021-04-06
PCT/US2022/023629 WO2022216796A1 (en) 2021-04-06 2022-04-06 Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin

Publications (1)

Publication Number Publication Date
MX2023011733A true MX2023011733A (es) 2023-10-13

Family

ID=83510391

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011733A MX2023011733A (es) 2021-04-06 2022-04-06 Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin.

Country Status (8)

Country Link
US (1) US20220323597A1 (es)
EP (1) EP4319811A1 (es)
JP (1) JP2024514506A (es)
AU (1) AU2022253888A1 (es)
BR (1) BR112023020562A2 (es)
CA (1) CA3214989A1 (es)
MX (1) MX2023011733A (es)
WO (1) WO2022216796A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
MX2018014175A (es) * 2016-05-17 2020-02-07 Abbvie Biotherapeutics Inc Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
US20210107969A1 (en) * 2019-07-09 2021-04-15 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer

Also Published As

Publication number Publication date
WO2022216796A1 (en) 2022-10-13
US20220323597A1 (en) 2022-10-13
CA3214989A1 (en) 2022-10-13
JP2024514506A (ja) 2024-04-02
EP4319811A1 (en) 2024-02-14
AU2022253888A9 (en) 2024-02-22
AU2022253888A1 (en) 2023-09-28
BR112023020562A2 (pt) 2023-12-05

Similar Documents

Publication Publication Date Title
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
MX2022004656A (es) Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
MX2021013661A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos.
EA201992781A1 (ru) Ингибиторы g12c kras и способы их применения
EP4295846A3 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MX2021005700A (es) Inhibidores de kras g12c y metodos de uso de los mismos.
MX2020010836A (es) Inhibidores de kras g12c y métodos para su uso.
MX2020011582A (es) Inhibidores de kras g12c y metodos para su uso.
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2019011148A (es) Metodos de tratamiento.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
NZ725595A (en) Compounds for treating brain cancer
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
PH12019500957A1 (en) Selective inhibitor of exon 20 insertion mutant egfr
MX2021015628A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
MX2022001249A (es) Tratamiento de tumores evasivos inmunitarios.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy